<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00205270</url>
  </required_header>
  <id_info>
    <org_study_id>H-2004-0240</org_study_id>
    <secondary_id>A561000</secondary_id>
    <secondary_id>PHARM/PHARMACY/PHARMACY</secondary_id>
    <nct_id>NCT00205270</nct_id>
  </id_info>
  <brief_title>Influenza Vaccine in Lung Transplant Patients</brief_title>
  <official_title>Antibody Responses to Influenza Vaccine in Pre- and Post-lung Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 5-year study was designed to investigate how antibody and T cell responses following&#xD;
      influenza vaccine compare among lung transplant patients, patients waiting for lung&#xD;
      transplantation, and healthy individuals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      [Note: there are 6 ClinicalTrials.gov records associated with this study, each representing a&#xD;
      different sub-study of the population over the 5-year period, please see NCT04533061,&#xD;
      NCT04533139, NCT04531787, NCT04530786, and NCT04531657 for related data]&#xD;
&#xD;
      Although pre-transplant immunization is routinely recommended, this recommendation is based&#xD;
      on little data. The primary objective of this study is to compare antibody responses in lung&#xD;
      transplant patients who receive influenza vaccine before transplant, within the first six&#xD;
      months of transplant, between 13 and 60 months post-transplant, and 110 months or beyond&#xD;
      transplant.&#xD;
&#xD;
      This prospective cohort study is to include immunization events performed over five years to&#xD;
      measure H1N1, H3N2, and B antibody responses to the influenza vaccine in pre- and post-lung&#xD;
      transplant patients. The pre-transplant patients will move to the post-transplant group as&#xD;
      the study progressed. Similarly, participants are allowed to move to the next&#xD;
      time-since-transplant group as time elapsed.&#xD;
&#xD;
      Serum was collected from participants prior to and two-four weeks following trivalent&#xD;
      inactivated influenza immunization for each season.&#xD;
&#xD;
      Geometric mean titers, seroprotection (antibody titer at least 1:40), seroconversion&#xD;
      (fourfold increase between pre and post), and mean fold increases will be compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody response to influenza vaccine</measure>
    <time_frame>Each season</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>T cell response to influenza vaccine antigens</measure>
    <time_frame>Each season for the first two seasons</time_frame>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">126</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Pre-transplant Vaccine</arm_group_label>
    <description>Cohort consists of individuals waiting for lung transplantation. Inactivated influenza vaccine will be administered intramuscularly annually.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0-6 Months Post-transplant Vaccine</arm_group_label>
    <description>Cohort consist of individuals who have received lung transplants and received inactivated influenza vaccine 0-6 months post transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>13-60 months Post-transplant Vaccine</arm_group_label>
    <description>Cohort consist of individuals who have received lung transplants and received inactivated influenza vaccine 13-60 months post transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Greater than 110 months Post-transplant Vaccine</arm_group_label>
    <description>Cohort consist of individuals who have received lung transplants and received inactivated influenza vaccine greater than 110 months post transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>Healthy controls to measure normal immune response to the influenza vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Influenza vaccine</intervention_name>
    <description>influenza vaccine 0.5 ml intramuscularly each season</description>
    <arm_group_label>0-6 Months Post-transplant Vaccine</arm_group_label>
    <arm_group_label>13-60 months Post-transplant Vaccine</arm_group_label>
    <arm_group_label>Greater than 110 months Post-transplant Vaccine</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Pre-transplant Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy adults and patients receiving care pre- or post-lung transplant at University of&#xD;
        Wisconsin Hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Receiving care pre- or post-lung transplant at University of Wisconsin Hospital&#xD;
&#xD;
          -  Healthy adult&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to eggs&#xD;
&#xD;
          -  Moderate to severe febrile illness&#xD;
&#xD;
          -  Active treatment for acute rejection&#xD;
&#xD;
          -  Received season's influenza vaccine prior to enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary S Hayney, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Dopp JM, Wiegert NA, Moran JJ, Francois ML, Radford KL, Thomas H, Love RB, Hayney MS. Effect of annual influenza immunization on antibody response in lung transplant patients. Prog Transplant. 2009 Jun;19(2):153-9.</citation>
    <PMID>19588665</PMID>
  </results_reference>
  <results_reference>
    <citation>Hayney MS, Moran J, Wiegert NA, Burlingham WJ. Lung transplant patients' T cell responses to influenza vaccine viruses between seasons. Vaccine. 2008 May 19;26(21):2596-600. doi: 10.1016/j.vaccine.2008.03.012. Epub 2008 Mar 31.</citation>
    <PMID>18420314</PMID>
  </results_reference>
  <results_reference>
    <citation>Moran JJ, Rose WE, Darga AJ, Rohde KA, Hayney MS. Persistence of influenza vaccine-induced antibodies in lung transplant patients between seasons. Transpl Infect Dis. 2011 Oct;13(5):466-70. doi: 10.1111/j.1399-3062.2011.00654.x. Epub 2011 May 27.</citation>
    <PMID>21615847</PMID>
  </results_reference>
  <results_reference>
    <citation>Severson JJ, Richards KR, Moran JJ, Hayney MS. Persistence of influenza vaccine-induced antibody in lung transplant patients and healthy individuals beyond the season. Hum Vaccin Immunother. 2012 Dec 1;8(12):1850-3. doi: 10.4161/hv.21735. Epub 2012 Aug 21.</citation>
    <PMID>22906937</PMID>
  </results_reference>
  <results_reference>
    <citation>Long AJ, Worzella SL, Moran JJ, Hayney MS. Influenza vaccine antibody response and 6-month persistence in lung transplant recipients using two definitions of seroprotection. Transplantation. 2015 Apr;99(4):885-9. doi: 10.1097/TP.0000000000000391.</citation>
    <PMID>25148380</PMID>
  </results_reference>
  <results_reference>
    <citation>Miller RM, Rohde KA, Tingle MT, Moran JJ, Hayney MS. Antibody responses to influenza vaccine in pre- and post-lung transplant patients. Clin Transplant. 2016 May;30(5):606-12. doi: 10.1111/ctr.12726. Epub 2016 Mar 20.</citation>
    <PMID>26928266</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pre or post-lung transplant</keyword>
  <keyword>Healthy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

